{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:03:20Z","timestamp":1761894200259},"reference-count":49,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Intensive chemotherapy regimens for children with acute lymphoblastic leukemia (ALL) have greatly improved, and the majority of children with precursor B-cell ALL are able to achieve a complete remission (CR), with an induction rate approaching 98% and a 5-year estimated event-free survival rate (EFS) of approximately 80%. Although there have been dramatic improvements over the last several decades in both the EFS and overall survival (OS) rates in young children with ALL, the results in adult clinical trials have not kept pace. Current adult treatment regimens result in CR rates in the 80% range, with EFS at 5 years of only 30%\u201340%. Adolescents and young adults represent a minority of patients enrolled onto either adult or pediatric clinical trials. As a result, little information is available regarding CR, EFS, and OS rates for this age group, and the appropriate treatment regimen for this group of patients remains elusive. Recent studies suggest that young adult patients have far superior outcomes when treated on more intensive pediatric regimens. In addition, new insights into the molecular pathogenesis of T cell ALL have led to new therapeutic strategies.<\/jats:p>","DOI":"10.1182\/asheducation-2005.1.123","type":"journal-article","created":{"date-parts":[[2005,11,22]],"date-time":"2005-11-22T20:29:34Z","timestamp":1132691374000},"page":"123-130","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia"],"prefix":"10.1182","volume":"2005","author":[{"given":"Daniel J.","family":"DeAngelo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111702182764500_R1","doi-asserted-by":"crossref","unstructured":"Conter V, Arico M, Valsecchi MG, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982\u20131995. Leukemia. 2000;14:2196\u20132204.","DOI":"10.1038\/sj.leu.2401963"},{"key":"2019111702182764500_R2","doi-asserted-by":"crossref","unstructured":"Gaynon PS, Trigg ME, Heerema NA, et al. Children\u2019s Cancer Group trials in childhood acute lymphoblastic leukemia: 1983\u20131995. Leukemia. 2000;14:2223\u20132233.","DOI":"10.1038\/sj.leu.2401939"},{"key":"2019111702182764500_R3","doi-asserted-by":"crossref","unstructured":"Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350:1535\u20131548.","DOI":"10.1056\/NEJMra023001"},{"key":"2019111702182764500_R4","doi-asserted-by":"crossref","unstructured":"Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211\u20131218.","DOI":"10.1182\/blood.V97.5.1211"},{"key":"2019111702182764500_R5","doi-asserted-by":"crossref","unstructured":"Chessells JM, Hall E, Prentice HG, Durrant J, Bailey CC, Richards SM. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia. 1998;12:463\u2013473.","DOI":"10.1038\/sj.leu.2400959"},{"key":"2019111702182764500_R6","doi-asserted-by":"crossref","unstructured":"Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025\u20132037.","DOI":"10.1182\/blood.V85.8.2025.bloodjournal8582025"},{"key":"2019111702182764500_R7","unstructured":"Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92:1556\u20131564."},{"key":"2019111702182764500_R8","unstructured":"Stock W, Yu D, Johnson J, et al. Intensified daunorubicin during induction and post-remission therapy for adults with acute lymphoblastic leukemia (ALL), results of CALGB 19802 [abstract]. Blood. 2003;102:379a."},{"key":"2019111702182764500_R9","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Thomas D, O\u2019Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101:2788\u20132801.","DOI":"10.1002\/cncr.20668"},{"key":"2019111702182764500_R10","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, O\u2019Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000;18:547\u2013561.","DOI":"10.1200\/JCO.2000.18.3.547"},{"key":"2019111702182764500_R11","doi-asserted-by":"crossref","unstructured":"Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2000;14:1307\u20131325.","DOI":"10.1016\/S0889-8588(05)70188-X"},{"key":"2019111702182764500_R12","doi-asserted-by":"crossref","unstructured":"Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075\u20134086.","DOI":"10.1200\/JCO.2004.10.050"},{"key":"2019111702182764500_R13","doi-asserted-by":"crossref","unstructured":"Durrant IJ, Richards SM, Prentice HG, Goldstone AH. The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000;14:1327\u20131352.","DOI":"10.1016\/S0889-8588(05)70189-1"},{"key":"2019111702182764500_R14","doi-asserted-by":"crossref","unstructured":"Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children\u2019s Cancer Group. Blood. 2003;101:3809\u20133817","DOI":"10.1182\/blood-2002-08-2454"},{"key":"2019111702182764500_R15","doi-asserted-by":"crossref","unstructured":"Schwartz CL, Thompson EB, Gelber RD, et al. Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia. J Clin Oncol. 2001;19:1040\u20131046.","DOI":"10.1200\/JCO.2001.19.4.1040"},{"key":"2019111702182764500_R16","unstructured":"Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood. 2000;95:3310\u20133322."},{"key":"2019111702182764500_R17","doi-asserted-by":"crossref","unstructured":"Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994;84:3122\u20133133.","DOI":"10.1182\/blood.V84.9.3122.3122"},{"key":"2019111702182764500_R18","doi-asserted-by":"crossref","unstructured":"Nachman J, Sather HN, Buckley JD, et al. Young adults 16\u201321 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer. 1993;71:3377\u20133385.","DOI":"10.1002\/1097-0142(19930515)71:10+<3377::AID-CNCR2820711741>3.0.CO;2-8"},{"key":"2019111702182764500_R19","doi-asserted-by":"crossref","unstructured":"Pullen J, Shuster JJ, Link M, et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia. 1999;13:1696\u20131707.","DOI":"10.1038\/sj.leu.2401555"},{"key":"2019111702182764500_R20","doi-asserted-by":"crossref","unstructured":"Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15:21\u201336.","DOI":"10.1016\/S0889-8588(05)70198-2"},{"key":"2019111702182764500_R21","unstructured":"Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia. 1991;5:196\u2013199."},{"key":"2019111702182764500_R22","doi-asserted-by":"crossref","unstructured":"Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605\u2013615.","DOI":"10.1056\/NEJM199808273390907"},{"key":"2019111702182764500_R23","doi-asserted-by":"crossref","unstructured":"Harrison CJ, Moorman AV, Broadfield ZJ, et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol. 2004;125:552\u2013559.","DOI":"10.1111\/j.1365-2141.2004.04948.x"},{"key":"2019111702182764500_R24","doi-asserted-by":"crossref","unstructured":"Aguiar RC, Sohal J, van Rhee F, et al. TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. M.R.C. Adult Leukaemia Working Party. Br J Haematol. 1996;95:673\u2013677.","DOI":"10.1046\/j.1365-2141.1996.d01-1946.x"},{"key":"2019111702182764500_R25","doi-asserted-by":"crossref","unstructured":"Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL\/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Munster Study Group. Blood. 1997;90:571\u2013577.","DOI":"10.1182\/blood.V90.2.571"},{"key":"2019111702182764500_R26","unstructured":"Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL\/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood. 2000;96:1094\u20131099."},{"key":"2019111702182764500_R27","doi-asserted-by":"crossref","unstructured":"Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774\u2013780.","DOI":"10.1200\/JCO.2003.02.053"},{"key":"2019111702182764500_R28","unstructured":"Stock W, Satjer H, Dodge R, Bloomfield CD, Larson RA, Nachman J. Outcome of adolescents and young adults with ALL: a comparison of Children\u2019s Cancer Group (CCG) and Cancer and Leukemia Group B (CALGB) regimens [abstract]. Blood. 2000;96:467a."},{"key":"2019111702182764500_R29","doi-asserted-by":"crossref","unstructured":"de Bont JM, Holt B, Dekker AW, van der Does-van den Berg A, Sonneveld P, Pieters R. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004;18:2032\u20132035.","DOI":"10.1038\/sj.leu.2403538"},{"key":"2019111702182764500_R30","doi-asserted-by":"crossref","unstructured":"Testi A, Valsecchi M, Conter V, et al. Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols [abstract]. Blood. 2004;104:539a.","DOI":"10.1182\/blood.V104.11.1954.1954"},{"key":"2019111702182764500_R31","doi-asserted-by":"crossref","unstructured":"Schiffer CA. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol. 2003;21:760\u2013761.","DOI":"10.1200\/JCO.2003.11.116"},{"key":"2019111702182764500_R32","doi-asserted-by":"crossref","unstructured":"Annino L, Vegna ML, Camera A, et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99:863\u2013871.","DOI":"10.1182\/blood.V99.3.863"},{"key":"2019111702182764500_R33","doi-asserted-by":"crossref","unstructured":"Bleyer A, Montello M, Budd T, Saxman S. National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation. Cancer. 2005;103:1891\u20131897.","DOI":"10.1002\/cncr.20995"},{"key":"2019111702182764500_R34","doi-asserted-by":"crossref","unstructured":"Matloub Y, Asselin BL, Stork L, et al. Outcome of children with T-cell acute lymphoblastic leukemia (T-ALL) and standard risk (SR) features: results of CCG 1952, CCG-1991 and POG 9404 [abstract]. Blood. 2004;104:195a.","DOI":"10.1182\/blood.V104.11.680.680"},{"key":"2019111702182764500_R35","doi-asserted-by":"crossref","unstructured":"Bleyer A. The adolescent and young adult gap in cancer care and outcome. Curr Probl Pediatr Adolesc Health Care. 2004;35:182\u2013217.","DOI":"10.1016\/j.cppeds.2005.02.001"},{"key":"2019111702182764500_R36","doi-asserted-by":"crossref","unstructured":"Bleyer A. Older adolescents with cancer in North America deficits in outcome and research. Pediatr Clin North Am. 2002;49:1027\u20131042.","DOI":"10.1016\/S0031-3955(02)00035-4"},{"key":"2019111702182764500_R37","doi-asserted-by":"crossref","unstructured":"Thomas DA, O\u2019Brien S, Cortes J, et al. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004;104:1624\u20131630.","DOI":"10.1182\/blood-2003-12-4428"},{"key":"2019111702182764500_R38","doi-asserted-by":"crossref","unstructured":"Hoelzer D, Gokbuget N, Digel W, et al. Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. Blood. 2002;99:4379\u20134385.","DOI":"10.1182\/blood-2002-01-0110"},{"key":"2019111702182764500_R39","doi-asserted-by":"crossref","unstructured":"Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol. 2003;21:3616\u20133622.","DOI":"10.1200\/JCO.2003.10.116"},{"key":"2019111702182764500_R40","doi-asserted-by":"crossref","unstructured":"Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002;1:75\u201387.","DOI":"10.1016\/S1535-6108(02)00018-1"},{"key":"2019111702182764500_R41","doi-asserted-by":"crossref","unstructured":"Radtke F, Wilson A, Stark G, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunit. 1999;10:547\u2013558.","DOI":"10.1016\/S1074-7613(00)80054-0"},{"key":"2019111702182764500_R42","doi-asserted-by":"crossref","unstructured":"Pui JC, Allman D, Xu L, et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity. 1999;11:299\u2013308.","DOI":"10.1016\/S1074-7613(00)80105-3"},{"key":"2019111702182764500_R43","doi-asserted-by":"crossref","unstructured":"Weng AP, Ferrando AA, Lee W, et al. C. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306:269\u2013271.","DOI":"10.1126\/science.1102160"},{"key":"2019111702182764500_R44","doi-asserted-by":"crossref","unstructured":"Graux C, Cools J, Melotte C, et al. Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet. 2004;36:1084\u20131089.","DOI":"10.1038\/ng1425"},{"key":"2019111702182764500_R45","doi-asserted-by":"crossref","unstructured":"Kisor DF, Plunkett W, Kurtzberg J, et al. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000;18:995\u20131003.","DOI":"10.1200\/JCO.2000.18.5.995"},{"key":"2019111702182764500_R46","unstructured":"Rodriguez CO, Jr., Mitchell BS, Ayres M, Eriksson S, Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002;62:3100\u20133105."},{"key":"2019111702182764500_R47","doi-asserted-by":"crossref","unstructured":"Kurtzberg J, Ernst TJ, Keating MJ, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005;23:3396\u20133403.","DOI":"10.1200\/JCO.2005.03.199"},{"key":"2019111702182764500_R48","doi-asserted-by":"crossref","unstructured":"Berg SL, Blaney SM, Devidas M, et al. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children\u2019s Oncology Group. J Clin Oncol. 2005;23:3376\u20133382.","DOI":"10.1200\/JCO.2005.03.426"},{"key":"2019111702182764500_R49","unstructured":"DeAngelo D, Yu D, Dodge RK, et al. A phase II study of 2-amino-9-b-D-arabinosyl-6-methoxy-9H-purine (506U78) in patients with relapsed or refractory T-lineage acute lymphoblastic leukiam (ALL) or lymphoblastic lymphoma (LBL): CALGB study 19801 [abstract]. Blood. 2002;100:198a."}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/123\/645106\/123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2005\/1\/123\/645106\/123.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T02:18:50Z","timestamp":1573957130000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2005\/1\/123\/19276\/The-Treatment-of-Adolescents-and-Young-Adults-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2005.1.123","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}